CY1112570T1 - Θεραπεια καρκινων με μετασταση - Google Patents

Θεραπεια καρκινων με μετασταση

Info

Publication number
CY1112570T1
CY1112570T1 CY20111101216T CY111101216T CY1112570T1 CY 1112570 T1 CY1112570 T1 CY 1112570T1 CY 20111101216 T CY20111101216 T CY 20111101216T CY 111101216 T CY111101216 T CY 111101216T CY 1112570 T1 CY1112570 T1 CY 1112570T1
Authority
CY
Cyprus
Prior art keywords
cancer treatment
compound
transitional cancer
tautomer
pharmaceutically acceptable
Prior art date
Application number
CY20111101216T
Other languages
Greek (el)
English (en)
Inventor
De Menezes Daniel Lopes
Carla Heise
Xiaοhua Xin
Original Assignee
Novartis Vaccines And Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36741085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112570(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines And Diagnostics, Inc. filed Critical Novartis Vaccines And Diagnostics, Inc.
Publication of CY1112570T1 publication Critical patent/CY1112570T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20111101216T 2005-01-27 2011-12-06 Θεραπεια καρκινων με μετασταση CY1112570T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64756805P 2005-01-27 2005-01-27
US66924505P 2005-04-06 2005-04-06
US72205305P 2005-09-29 2005-09-29
EP06733986A EP1845990B1 (en) 2005-01-27 2006-01-27 Treatment of metastasized tumors

Publications (1)

Publication Number Publication Date
CY1112570T1 true CY1112570T1 (el) 2016-02-10

Family

ID=36741085

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101216T CY1112570T1 (el) 2005-01-27 2011-12-06 Θεραπεια καρκινων με μετασταση

Country Status (22)

Country Link
US (2) US20060183750A1 (enExample)
EP (2) EP1845990B1 (enExample)
JP (2) JP5371246B2 (enExample)
KR (1) KR101387985B1 (enExample)
CN (1) CN103893181A (enExample)
AT (1) ATE526025T1 (enExample)
AU (1) AU2006208012B2 (enExample)
BR (1) BRPI0607285A2 (enExample)
CA (1) CA2596084A1 (enExample)
CY (1) CY1112570T1 (enExample)
DK (1) DK1845990T3 (enExample)
ES (2) ES2374570T3 (enExample)
IL (1) IL184866A0 (enExample)
MA (1) MA29266B1 (enExample)
MX (1) MX2007009099A (enExample)
NO (1) NO20074360L (enExample)
PL (2) PL2301546T3 (enExample)
PT (2) PT2301546E (enExample)
SG (1) SG173317A1 (enExample)
SI (1) SI2301546T1 (enExample)
TN (1) TNSN07294A1 (enExample)
WO (1) WO2006081445A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334641T3 (es) 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
NZ524717A (en) 2000-09-11 2004-09-24 Chiron Corp Quinolinone derivatives
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
PT1885187E (pt) * 2005-05-13 2013-12-16 Novartis Ag Métodos para o tratamento de cancro resistente a fármacos
RU2425041C2 (ru) * 2005-05-23 2011-07-27 Новартис Аг Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она
AR070924A1 (es) * 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
US20120064008A1 (en) * 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
TR201819653T4 (tr) * 2010-04-16 2019-01-21 Novartis Ag Karaciğer kanserinin tedavisinde kullanılmaya yönelik organik bileşik.
KR20140023358A (ko) * 2011-05-19 2014-02-26 노파르티스 아게 선양 낭성 암종의 치료에 사용하기 위한 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온
MX2014009303A (es) * 2012-01-31 2014-10-14 Novartis Ag Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
CN109689649B (zh) * 2016-07-14 2022-07-19 百时美施贵宝公司 经二环杂芳基取代的化合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
EP0627940B1 (en) * 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
WO1997048697A1 (en) * 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
BR9711805A (pt) 1996-06-20 2002-01-15 Regents The Univesity Of Texas Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
WO2001028993A2 (en) 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
EP1226136B1 (en) 1999-10-19 2004-12-29 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2003523390A (ja) 2000-02-25 2003-08-05 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1351946A2 (en) * 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
ES2334641T3 (es) 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
NZ524717A (en) * 2000-09-11 2004-09-24 Chiron Corp Quinolinone derivatives
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US7838527B2 (en) 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
US6774327B1 (en) * 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
KR101224410B1 (ko) * 2003-11-07 2013-01-23 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 퀴놀리논 화합물을 합성하는 방법
RU2377988C2 (ru) * 2004-02-20 2010-01-10 Новартис Вэксинес Энд Дайэгностикс, Инк. Модуляция воспалительных и метастатических процессов
US20060261307A1 (en) * 2005-05-18 2006-11-23 Black D J Water Activated Organic Scavenger
KR102639757B1 (ko) 2017-01-09 2024-02-23 엘지이노텍 주식회사 카메라 모듈 및 이를 포함하는 광학기기

Also Published As

Publication number Publication date
SG173317A1 (en) 2011-08-29
US20060183750A1 (en) 2006-08-17
EP1845990B1 (en) 2011-09-28
IL184866A0 (en) 2007-12-03
PT2301546E (pt) 2014-12-18
KR101387985B1 (ko) 2014-04-25
EP2301546B1 (en) 2014-09-10
AU2006208012B2 (en) 2011-08-04
EP2301546A1 (en) 2011-03-30
MA29266B1 (fr) 2008-02-01
SI2301546T1 (sl) 2015-01-30
JP5371246B2 (ja) 2013-12-18
ATE526025T1 (de) 2011-10-15
CA2596084A1 (en) 2006-08-03
EP1845990A4 (en) 2008-04-30
PL1845990T3 (pl) 2012-02-29
JP2013177464A (ja) 2013-09-09
PL2301546T3 (pl) 2015-03-31
KR20070118596A (ko) 2007-12-17
ES2525670T3 (es) 2014-12-29
AU2006208012A1 (en) 2006-08-03
ES2374570T3 (es) 2012-02-17
CN103893181A (zh) 2014-07-02
MX2007009099A (es) 2007-09-13
JP2008528617A (ja) 2008-07-31
EP1845990A2 (en) 2007-10-24
US20100173873A1 (en) 2010-07-08
WO2006081445A3 (en) 2007-01-11
TNSN07294A1 (en) 2008-12-31
PT1845990E (pt) 2011-12-23
WO2006081445A2 (en) 2006-08-03
BRPI0607285A2 (pt) 2009-08-25
NO20074360L (no) 2007-10-25
DK1845990T3 (da) 2012-01-02
HK1155664A1 (en) 2012-05-25

Similar Documents

Publication Publication Date Title
CY1112570T1 (el) Θεραπεια καρκινων με μετασταση
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
IL184951A0 (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
TW200640883A (en) Compounds for the treatment of proliferative disorders
ATE469158T1 (de) Heteroalkylgebundene pyrimidinderivate
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
MX2009009574A (es) Tratamiento de melanoma.
TW200716570A (en) Compounds for the treatment of proliferative disorders
WO2005070043A3 (en) Methods for treating non-melanoma cancers with paba
ECSP066986A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
WO2008011113A3 (en) Thiadiazolidinone derivatives
WO2006044975A3 (en) Compositions and their use as anti-tumor agents
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
TW200735866A (en) Compounds for the treatment of proliferative disorders
EP1364652A4 (en) DRUGS FOR LUNG CANCER
ATE435647T1 (de) Rutheniumkomplexe zur krebsbehandlung
TW200706174A (en) Indole compounds
TW200706536A (en) Indole compounds